Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir disoproxil fumarate + lamivudine + efavirenz
- Development stage
- Approved
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenofovir disoproxil fumarate + lamivudine + efavirenz is a fixed-dose combination antiretroviral medication used as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35 kg. The combination contains three active ingredients with distinct mechanisms of action targeting HIV reverse transcriptase. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while both lamivudine and tenofovir disoproxil fumarate are nucleo(t)side reverse transcriptase inhibitors (NRTIs). Together, these agents inhibit HIV replication by blocking the activity of reverse transcriptase, an enzyme essential for viral replication. This regimen does not cure HIV but helps suppress viral load and delay disease progression[4][5][7][8].
- Brand names
- SymfiSymfi Lo
- Other names
- efavirenz, lamivudine and tenofovir disoproxil fumarate tabletsEFV/3TC/TDF
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on tenofovir disoproxil fumarate + lamivudine + efavirenz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir disoproxil fumarate + lamivudine + efavirenz.